9 Leukemia Clinical Trials in Augusta, GA (2026)

Q: How do I join a clinical trial in Augusta?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Augusta research site will contact you.

Recruiting Leukemia Studies in Augusta

NCT05735184Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will inve...

Augusta, GAPHASE1420 participantsKura Oncology, Inc.

View Study Details

NCT06051409Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kina...

Augusta, GAPHASE3350 participantsAscentage Pharma Group Inc.

View Study Details

NCT06788756Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with ...

Augusta, GAPHASE2312 participantsMoleculin Biotech, Inc.

View Study Details

NCT04260022Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic pha...

Augusta, GAPHASE1242 participantsAscentage Pharma Group Inc.

View Study Details

NCT06163430Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with pr...

Augusta, GAPHASE1180 participantsTerns, Inc.

View Study Details

NCT06001788Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the...

Augusta, GAPHASE1171 participantsKura Oncology, Inc.

View Study Details

NCT02781883Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with ...

Augusta, GAPHASE2108 participantsBio-Path Holdings, Inc.

View Study Details

NCT05143840Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...

Augusta, GAPHASE2100 participantsAugusta University

View Study Details

NCT06672146Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed...

Augusta, GAPHASE293 participantsNational Cancer Institute (NCI)

View Study Details

About Leukemia Clinical Trials in Augusta

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 9 leukemia clinical trials recruiting participants in Augusta, GA. These studies are seeking a combined 1,976 participants. Research is being sponsored by Kura Oncology, Inc., Ascentage Pharma Group Inc., Moleculin Biotech, Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Augusta — FAQ

Are there leukemia clinical trials in Augusta?

Yes, there are 9 leukemia clinical trials currently recruiting in Augusta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Augusta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Augusta research site will contact you about next steps.

Are clinical trials in Augusta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Augusta studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 9 active trials in Augusta are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 21, 2026 from ClinicalTrials.gov